Investors & Media
At Bachem, we believe in open and transparent dialogue with both the financial community and public media.
As a company listed on the Swiss stock exchange, we provide regular information on the strategy and current situation of our company as well as on planned and expected future developments.
On these pages, we have compiled the most important information for shareholders and representatives of the capital markets as well as for media representatives, and we update it regularly.
Your contact at Bachem for investor and media enquiries:
Dr. Daniel Grotzky
Head Group Communications
Bachem Holding AG
Tel +41 58 595 2021 (Direct: -3806)
Investor enquiries: firstname.lastname@example.org
Media enquiries: email@example.com
Please state your outlet (financial institution or media outlet) and any relevant deadline for information when reaching out to us.
to our press releases and investor news
Click here >>
Latest financial news
Bachem with slight decline in sales to CHF 234.9 million in the first half of 2022. Strong growth expected in the second half of the year.
Board of Directors
Bachem’s Board of Directors are responsible for defining the corporate strategy and are elected by the company shareholders.
Corporate Executive Committee
Responsible for managing Bachem worldwide and for implementing policies and strategies as defined by the Board of Directors.
Code of Conduct
The basis for the behavior which we demonstrate day by day. This Code of Conduct forms an integral part for everyone at Bachem.
Articles of Association of Bachem Holding AG
As a stock listed company, Bachem is as a company reviewed and commented upon by analysts on a regular basis. According to our best knowledge, the hereunder mentioned finance institutions prepare and issue Bachem related reports. There is no guarantee regarding the completeness and correctness of the list, although we strive to maintain and update it. Bachem does not comment on any analyst report and disclaims any liability in relation with statements or recommendations made therein as well as transactions based thereon.
Baader Helvea AG
Leonildo Delgado, PhD,
Director Equity Research
+41 43 388 9226
+44 020 7984 8274
Mirabaud Securities Limited
Dr. Anja Pomrehn,
Senior Medical Technology and Chemical Equity Analyst
+41 44 798 24 68
+41 44 520 06 29
Research Partners AG
Dr. Martin Vögtli
+41 44 533 40 30
+41 44 238 95 61
Senior Analyst Equity Research
+41 58 283 70 21
Daniel Buchta, MSc
+41 44 292 37 34